Forest Clinical Trials Registry Launches With Antidepressant Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest's registry website, required under a settlement with the New York Attorney General, currently includes summaries of pediatric and adolescent studies of Lexapro and Celexa, and listings for all of Forest's open Phase III and IV trials.
You may also be interested in...
Desmoteplase Approval For Stroke Expected In 2009, Forest Says
Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.
Desmoteplase Approval For Stroke Expected In 2009, Forest Says
Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.
Forest Settles With Spitzer, Will Post All Phase III-IV Results On-Line
Forest Labs has agreed to post summaries of all Phase III and Phase IV trials on the Internet to resolve an investigation into the company by New York Attorney General Eliot Spitzer